Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus CEFMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus CEFMAX.
CEFAZOLIN AND DEXTROSE vs CEFMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic